|Send to printer »|
Columns : Mar 1, 2010 ( )
Realistic Expectations Likely to Prevail in 2010
As Economy Recovers, Firms in Sector Remain Cautiously Optimistic about Future Growth!--h2>
The biotech industry is starting the new decade with good reason for cautious optimism. Based on results from our current 7th Annual Report and Survey of Biomanufacturing, most companies are more confident, but also more realistic: 2010 will bring good results, but managers are expecting better performance from the same staff. Some of last year’s budgetary shifts are becoming solid trends that are defining how biopharma will evolve over the next few years. Key developments in 2010 will include advances in science, technology, the economy, and regulations.
Overall, 2010 will be a good year for the biotechnology and biopharmaceutical industries. The firms that remain will be viable, relatively insulated, and in a position for solid future growth.
© 2016 Genetic Engineering & Biotechnology News, All Rights Reserved